Timothy M. Mayleben

Tim Mayleben is President and Chief Executive Officer of Esperion Therapeutics (NASDAQ: ESPR) and has been a member of the board of directors since February 2010. Prior to joining Esperion, Tim was President, CEO and a Director of Aastrom Biosciences, Inc. (NASDAQ: ASTM). Previously, Tim was President, Chief Operating Officer and a director of NightHawk Radiology Holdings, Inc. Prior to joining Nighthawk, Tim was the COO of the original Esperion, until its acquisition by Pfizer in 2004. Tim is an advisor to, investor in, and member of the board of directors of several life science companies, including DeNovo Sciences, kaleo, Lycera Corporation and Marinus Pharmaceuticals. Tim earned an M.B.A., with distinction, from the J.L. Kellogg Graduate School of Management at Northwestern University, and a B.B.A. from theUniversity of Michigan, Ross School of Business.